The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology announced that its President and CEO, Marianne De Backer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 7:45 a.m. ET.
The session will be webcast live, allowing viewers to hear De Backer discuss the company's recent developments and strategy in hepatitis delta and oncology. The event is expected to provide stakeholders with an update on Vir Biotechnology's corporate outlook and pipeline priorities.
View post on X Loading...
Vir Biotechnology recently marked 10 years in business, outlining key scientific advances and organizational milestones in a company timeline. The firm also reported over $1.0 billion in cash as it advanced its CHD and oncology portfolios in its Q2 2026 financial results. These developments set the stage for the company’s updated strategy shared at the upcoming conference.